US-based medical device company CardioKinetix closed a two tranche round of series E financing worth $44m on Tuesday. The round was led by venture capital (VC) firms SV Life Sciences and New Leaf Venture Partners. Further participation came from financial services firm JP Morgan’s corporate venturing unit, JP Morgan Partners, and H&Q Healthcare Investors, the…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
